Biotech companies, particularly emerging biotech companies, face a dual challenge: they must demonstrate progress in the difficult task of drug development while at the same time raising capital to feed the process. In the United States, that difficulty has been heightened by the U.S. Food and Drug Administration’s prohibitions against preapproval promotion of a drug.